# A Study of MK-6194 (PT101) in Participants With Active Ulcerative Colitis (UC) (MK-6194-002)

> **NCT04924114** · PHASE1 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 57 (actual)

## Conditions studied

- Ulcerative Colitis

## Interventions

- **DRUG:** MK-6194
- **DRUG:** MK-6194-matching placebo

## Key facts

- **NCT ID:** NCT04924114
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-10-14
- **Primary completion:** 2024-01-08
- **Final completion:** 2024-07-15
- **Target enrollment:** 57 (ACTUAL)
- **Last updated:** 2025-08-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04924114

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04924114, "A Study of MK-6194 (PT101) in Participants With Active Ulcerative Colitis (UC) (MK-6194-002)". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT04924114. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*